Medical Condition News

RSS

Researchers design new treatment approach for invasive brain tumors

Researchers from Emory and the Georgia Institute of Technology have designed a new treatment approach that appears to halt the spread of cancer cells into normal brain tissue in animal models.

29 Mar 2012

Study explores the processing of body pictures in binge eating

An investigation published in the current issue of Psychotherapy and Psychosomatics explores the processing of body pictures in binge eating.

29 Mar 2012

New strategy to ensure that GPs advise heavy drinkers to cut down

The new UK alcohol strategy includes a plan to ensure that General Practitioners (GPs) advise heavy drinkers to cut down.

29 Mar 2012

Regulatory agencies approve plans for e-Therapeutics' ETS2101 phase I trials in cancer

e-Therapeutics plc announces that regulatory agencies in the UK and the US have approved plans for phase I trials of the Company's anti-cancer drug ETS2101 and that enrolment of patients into trials in these two countries will begin shortly.

29 Mar 2012

Bariatric surgery may eliminate need for diabetes medication

Diabetes has become an epidemic in the United States, with the number of cases tripling over the last three decades. Most of those cases are Type 2 diabetes, which is linked to obesity and can lead to serious medical issues that range from heart disease to renal failure, blindness, and more.

29 Mar 2012

Researchers describe unexpected role of p75NTR in type 2 diabetes

Scientists at the Gladstone Institutes have discovered a key protein that regulates insulin resistance-the diminished ability of cells to respond to the action of insulin and which sets the stage for the development of the most common form of diabetes. This breakthrough points to a new way to potentially treat or forestall type 2 diabetes, a rapidly growing global health problem.

29 Mar 2012

EMA grants orphan designations to Ultragenyx UX001, UX003 for treatment of HIBM and MPS 7

Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7.

29 Mar 2012

Bristol-Myers Squibb, Meso Scale Discovery collaborate to advance AD research

Bristol-Myers Squibb Company and Meso Scale Discovery today announced they have entered an agreement to develop diagnostic assays that will measure cerebrospinal fluid biomarkers for use in Alzheimer's disease research.

29 Mar 2012

Gene therapy improves chylomicron metabolism in LPLD patients

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today data demonstrating that one-time administration of the gene therapy Glybera (alipogene tiparvovec) is able to markedly improve chylomicron (fat particles in the blood) metabolism following consumption of a low fat meal.

29 Mar 2012

Affymetrix' GeneChip technology incorporated into Lineagen's FirstStepDx genetic evaluation service

Affymetrix, Inc. and Lineagen, Inc., an innovative molecular diagnostics company focused on complex, genetically linked disorders, today announced the companies have signed an agreement to incorporate Affymetrix' GeneChip technology into Lineagen's next-generation FirstStepDx, a genetic evaluation service for individuals with developmental delay (DD), intellectual disability (ID), and autism spectrum disorders (ASD).

29 Mar 2012

Althea provides Allena exclusive worldwide rights to broad hyperoxaluria portfolio

Allena Pharmaceuticals, Inc., and Althea Technologies today announced a licensing agreement under which Allena has obtained the exclusive worldwide rights to Althea's broad hyperoxaluria portfolio including product patents, regulatory information and development data related to oxalate degrading enzymes.

29 Mar 2012

MabCure retains CUNY CAT to evaluate monoclonal antibodies against ovarian cancer

MabCure Inc., a leading developer of antibody-based technology for the diagnosis and treatment of ovarian, prostate, colorectal and other cancers, has retained the CUNY Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents.

29 Mar 2012

Stem Cells reports results of Neuralstem ALS Phase I trial

Neuralstem, Inc. announced that safety results from the first 12 patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) to receive its stem cells were reported online in the peer-reviewed publication, Stem Cells, on March 13th.

29 Mar 2012

Meditation decreases depression, anxiety and stress in school teachers

Schoolteachers who underwent a short but intensive program of meditation were less depressed, anxious or stressed - and more compassionate and aware of others' feelings, according to a UCSF-led study that blended ancient meditation practices with the most current scientific methods for regulating emotions.

29 Mar 2012

Researchers profile genetic changes in cancer with drug sensitivity

In the largest study of its kind, researchers have profiled genetic changes in cancer with drug sensitivity in order to develop a personalised approach to cancer treatments. The study is published in Nature on Thursday 29 March 2012.

29 Mar 2012

Paramedics are probably right when they suspect strokes

If a paramedic suspects a patient is having a stroke, the paramedic is probably right, a Loyola University Medical Center study has found.

29 Mar 2012

NEJM publishes results from Amgen's brodalumab Phase 2 trial on plaque psoriasis

Amgen announced today that results from a Phase 2 trial evaluating the safety and efficacy of brodalumab in 198 patients with moderate to severe plaque psoriasis were published in the New England Journal of Medicine.

29 Mar 2012

MESO-1 device can help in diagnosis and treatment of cancer

A new device designed to more effectively produce DNA samples for genetic testing from slide-mounted tissue samples is better equipped than most models on the market to help in the diagnosis and treatment of cancer.

29 Mar 2012

Nature journal publishes first volume of Cancer Cell Line Encyclopedia

The goal of cancer treatment is to match the right drug to the right target in the right patient. But before such "personalized" drugs can be developed, more knowledge is needed about specific genomic alterations in cancers and their sensitivity to potential therapeutic agents.

29 Mar 2012

Single-port laparoscopic appendectomy performed at Valley Presbyterian Hospital

Surgeons at Valley Presbyterian Hospital (VPH) recently performed the hospital's first-ever single-port laparoscopic appendectomy, a minimally invasive surgical procedure for removing an infected appendix, which reduces scarring and healing time because it requires only one incision, Gustavo Valdespino, VPH president and CEO, announced today.

29 Mar 2012